ALPHA-METHYLDOPA (a-methyl-3,4-di-IA hydroxy-L-phenylalanine [Aldomet]) is a useful antihypertensive agent with sedative and aromatic L-amino decarboxylase-inhibiting properties.'-7 It has several advantages over other potent antihypertensive drugs in current use. Reduction in blood pressure is achieved gradually and occurs in the lying as well as in the standing position. The lack of marked postural or exertional hypotension makes a-methyldopa particularly suitable for patients with coronary or cerebral artery disease, in whom sudden reduction in blood pressure may be disastrous. Symptoms of sympathetic blockade are uncommon, and renal vascular resistance is reduced,8 making it a potentially useful drug in the management of hypertension in patients with renal failure. On the other hand, in certain patients, rapid development of tolerance to the hypotensive effects of a-methyldopa has been noted,3 9-13 and in other patients little or no hypotensive effect is achieved. The mechanisms involved are unknown. The present clinical and metabolic study was undertaken to investigate the correlation between the metabolism of a-methyldopa and clinical response to the drug, and particularly to ascertain whether the development of tolerance could be related to changes
in drug metabolism occurring during chronic administration of the drug. The effect of amethyldopa on aromatic L-amino acid decarboxylase at the start of treatment and after prolonged treatment was also studied.
Methods
Twenty hypertensive patients were selected from the Joseph Earle Moore Clinic, Johns Hopkins Hospital, and from the Hypertension Clinic of the Baltimore City Hospitals. Their ages ranged from 25 to 59 years (mean, 47). All had standing diastolic blood pressures exceeding 110 mm Hg during a period on placebo treatment. None had malignant hypertension, signs of cardiac failure, clinical evidence of liver disease, or urea nitrogen exceeding 40 mg/100 ml of blood.
One patient was considered to have renal hypertension (E.H.) and another (D.H.) had undergone unilateral nephrectomy for chronic pyelonephritis 4 years previously. The diagnosis for the remainder was essential hypertension. Intravenous pyelography and appropriate tests to exclude pheochromocytoma were carried out in all patients. Most of the subjects had renal scans and some had undergone "split" renal function studies. One patient (B.G.) was a diabetic and continued to receive digitalis and tolbutamide (which she had been taking for several years) throughout the study.* Eight patients had been treated with a-methyldopa previously, but none had received it within 3 months of the start of the study. Some characteristics of the group are set out in table 1. Standing and lying blood pressures were always measured by the same observer (L.F.P.) with a standard arm cuff. The diastolic pressure was taken as the point of muffling of the Korotkoff sounds.
All antihypertensive drugs were withdrawn for at least 3 weeks before the study began. The *Patients M.T. and A.W. received barbiturates for a few days in the middle of the study period, that is, when metabolic studies were not in progress. M.R. took salicylates intermittently but not during metabolic studies.
Circulation, Volume XXXIV, August 1966 *Two-hour endogenous creatinine clearance. Mean of two determinations before and after treatment with a-methyldopa. tPrevious therapy: Th = thiazide, Gu = guanethidine, Res = reserpine, A = methyldopa, Hy = bydralazine. patients were then admitted to the Clinical Research Ward of the Johns Hopkins Hospital for metabolic studies. A diet low in protein (with no cheese, eggs, fish, or meat except for turkey) and constant in tyrosine and tryptophan was given, and oral loads of 10 g of L-tyrosine and 5 g of L-tryptophan were given on successive days in fruit juice with breakfast. Urine was collected for 8 hours following ingestion of the amino acids and assayed for tyramine and tryptamine content. Alpha-methyldopa, 250 mg, was then administered four times daily for 2 days after which the loading with tyrosine and tryptophan was repeated 1 hour after a single oral dose of 1.5 g of the drug. Urine was again collected for 8 hours after administration of the amino acids. The next day the patients were given orally 500 mg of a-methyldopa containing 20 uc of 2-14C-labeled drug, following an overnight fast (in some cases only 10 ,uc was given). Breakfast was given 45 minutes later, and blood was drawn 2, 4, 6, and 8 hours after the tracer dose was administered. Urine was collected from 0 to 24 hours and 24 to 48 hours in all subjects, and in some, stools were collected for 4 days. When these studies were complete, the patients were discharged, and the blood pressure recorded in Circulation, Volume XXXIV, August 1966 the clinic at weekly and later at 2-week intervals. Treatment with a-methyldopa was continued, and the dose was increased as rapidly as possible to a maximum maintenance dose of 3.0 g daily, depending on the blood pressure and side effects. Following treatment with a-methyldopa for 3 months, the patients were readmitted to the research ward, and the studies described were repeated, except that the control tyramine and tryptamine estimations were not carried out. Four days before the second admission the dose of a-methyldopa was reduced in all cases to 250 mg four times daily. When the studies had been completed, the patients were discharged on placebo tablets and the blood pressure was recorded at several clinic visits before administration of active drugs was reinstituted.
Analytical Methods
Urine samples were acidified to pH 3.0 to 4.0 with hydrochloric acid. Tyramine and tryptamine were assayed fluorometrically by the methods of Udenfriend14 and Sjoerdsma and associates. 15 Venous blood was drawn into tubes containing heparin, centrifuged, and the plasma was separated. All blood and urine samples were stored frozen until time of analysis. Stools were refriger- ated for periods of up to 18 hours, and then stored frozen. Measurements of plasma and stool radioactivity and the isolation and assay of the urinary metabolites of a-methyldopa were carried out as described previously by Buhs and associates.16 Results
Clinical Response
The percentage reduction in blood pressure is given in table 2 for the first month of treatment, for the second and third months, and for the entire treatment period. The average of the mean* of standing and lying blood pressures was calculated for each patient, and changes on treatment related to the corresponding control blood pressure on placebo measured before and after treatment with amethyldopa. The changes in mean standing blood pressure for the whole group are shown in figure 1 . These data are based on the blood pressures recorded in the clinics and Reduction in standing mean blood pressure during the first month, and second and third months of treatment with a-methyldopa.
do not include readings taken during hospital admissions. Solely for the purpose of analysis, a good response was arbitrarily defined retrospectively as a reduction in mean blood pressure of more than 18%, a moderate response as 13 to 18% reduction, and a poor response as less than 13% reduction. Thus five patients were classed as having a good response, 10 as moderate, and five as poor. In four patients who developed tolerance to the hypotensive action of a-methyldopa (E.B., D.B., A.W., and J.W.), the mean reduction in blood pressure fell from 24% during the first month of treatment to only 9% during the second and third months. In one of these patients ( Metabolism of a-Methyldopa Table 3 shows the percentage of the administered dose of 2-14C-labeled a-methyldopa Circulation, Volume XXXIV, August 1966 *Mean blood pressure = diastolic + 1 (systolic minus diastolic). recovered in the urine and stools and appearing in the plasma at 2, 4, 6, and 8 hours. There was considerable variation in both the urinary recovery and in plasma radioactivity, not only from patient to patient, but also in the same patient at different times. The mean percentage of urinary excretion of a-methyldopa and its metabolites in the first 24 hours at initial study was 27.9% and in the first 48 hours was 30.6%. The figures at final study were similar. The mean plasma radioactivity (corrected for body surface area-see footnote, table 3) at 2, 4, 6, and 8 hours during initial study was 2.5%, 2.3%, 1.7% and 1.0% of the administered dose. The means at final study were almost identical. The mean percentage recovery in the stools was 34.6% for all data combined, and 39.3% if one eliminates the values of 0.1. and M.T., which are so low as to suggest incomplete collections.
The free and conjugated a-methyldopa, 3methoxy-a-methyldopa, neutral fraction, and free and total base in the 0 to 24-hour samples of urine are shown in table 4 expressed as percentages of the total urinary radioactivity recovered. Although the general pattern of excretion of these metabolites is well defined, there were substantial individual differences in the percentages of some of the minor metabolites and considerable variation in some patients between the initial and final studies.
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There was no significant difference between the proportions of a-methyldopa, a-methyldopa-O-sulfate, neutral fraction, or free and conjugated base fractions at the initial and final studies. Considering both studies together, approximately 40% of the radioactivity recovered in the urine was present as unchanged a-methyldopa, 31% as a-methyldopa-0-sulfate, 9% as a neutral fraction, 3% as free base, and 3% as conjugated base. There was, however, a statistically significant increase in the percentage of 3-methoxy-a-methyldopa recovered after chronic administration of the drug compared with that found on the initial study. The mean increase was 43% (P < 0.001). The individual changes in the percentage urinary excretion of 3-methoxy-a-methyldopa are shown in figure 3 where it can be seen that there was an increase in every patient but one (M.R.).
Inhibition of Aromatic L-amino Acid Decarboxylase
Following treatment with a-methyldopa during the initial study, the urinary excretion of tyramine was reduced in every patient (mean level 39.7% of control; range 13 to 87%). The reduction of tryptamine was less than that of tyramine, being 50% of control (range 8.5% *Initial studies were carried out at the beginning of treatment with a-methyldopa; final studies were those carried out after treatment with 3 g a-methyldopa daily for 3 months. Urinary excretion of tyramine following oral load of 10 Urinary excretion of tryptamine following oral load of g of tyrosine before, at the beginning of, and after 3 5 g of tryptophan before, at the beginning of, and months' treatment with a-methyldopa. Percentage reduction in urinary excretion of tyramine at beginning of, and after 3 months' treatment with a-methyldopa. Percentage reduction in urinary excretion of tryptamine at beginning of, and after 3 months' treatment with a-methyldopa.
tyrosine as the substrate showed a continued excellent hypotensive response to a-methyldopa. There was no correlation between the inhibition of decarboxylase with tyrosine as the substrate and that with tryptophan as substrate ( fig. 8) , and there was no correlation between the degree of hypotensive action and inhibition of decarboxylase with either amino acid as substrate. Since a-methyldopa is itself decarboxylated to a-methyldopamine, a correlation was sought between the percentage reduction in urinary tyramine and tryptamine and the percentage of total and free base fractions of a-methyldopa isolated from the first 24-hour samples of urine, the base fraction having previously been shown to consist mainly of a-methyldopamine.16 No significant correlation could be found. There was also no correlation between the inhibition of decarboxylase and plasma concentrations of 14C-labeled a-methyldopa and its metabolites. Lack of correlation between percentage reduction in urinary excretion of tyramine and of tryptamine following treatment with a-methyldopa.
Correlations Between Clinical Response and Metabolism of a-Methyldopa
No significant relationship could be established between the plasma or urinary recovery of labeled a-methyldopa and its metabolites (except apparently 3-methoxy-a-methyldopa) and the hypotensive action of the drug. Not only was there no characteristic pattern of urinary excretion of the metabolites of amethyldopa associated with a good or poor hypotensive response, but there was no relationship between the excretion pattern and the development of tolerance or increased hypotensive effect.
As mentioned above, there was a significant increase in the percentage of urinary 3methoxy-a-methyldopa following the chronic administration of methyldopa. Moreover, there was a significant positive correlation between the percentage of 3-methoxy-a-methyldopa at the final study and the mean overall reduction in blood pressure (correlation coefficient r = 0.45, P < 0.05). Statistically significant correlations were also found between the excretion of 3-methoxy-a-methyldopa and the reductions in mean standing blood pressure, mean standing diastolic, and mean standing systolic blood pressures (table 6) but not with the corresponding supine blood pressures.
Discussion
These findings indicate that the absorption and biotransformation of orally administered a-methyldopa are irregular. The urinary recovery of labeled drug and its metabolite may vary from time to time in the same patient by as much as threefold, and the recovery in plasma (table 3) suggests considerable variation in the rate of absorption of the drug. These observations confirm and extend previous findings. 3 16, 17 It has not been possible to associate poor clinical response with inadequate absorption of a-methyldopa, although correlations may possibly have been missed since only isolated observations were made. The lack of correlation between plasma concentrations of the drug and the clinical response was noted by Sjoerdsma and asso-ciates17 and is compatible with the hypothesis 316 a that metabolites of methyldopa rather than the parent drug are responsible for its hypotensive action. Individual variation in the metabolism of a-methyldopa does not appear to be related to clinical response, and specifically, the development of tolerance to the hypotensive action of a-methyldopa cannot be explained on a metabolic basis. The pattern of urinary metabolites of a-methyldopa in this study is generally similar to that previously reported by Buhs and associates,'6 except that the percentages of all urinary metabolites except a-methyldopa-O-sulfate were somewhat higher in the present study. It has been suggested that the bypotensive action of a-methyldopa is mediated through the decarboxylated metabolites a-methyldopamine'7 and a-methyl-norepinephrine.1>21
Since decarboxylation is necessary for the formation of these metabolites, it might be expected that patients with marked inhibition of decarboxylase (as judged by low urinary levels of tyramine and tryptamine) would form only small amounts of a-methyldopamine and a-methyl-norepinephrine and hence would show less reduction in blood pressure. In fact, certain patients with marked inhibition of decarboxylase with tyrosine and tryptophan as substrates (for example, D.H., E.H.) demonstrated good clinical responses. Furthermore, no correlation was found between percentage recovery of base and reduction in blood pressure.
The decarboxylase inhibiting actions of amethyldopa are thought to be dissociated from the hypotensive and norepinephrine depleting effects.17 ' 19, 22-24 The rate-limiting step in the synthesis of norepinephrine from tyrosine is considered to be the hydroxylation of tyrosine to 3,4,-dihydroxy-L-phenylalanine (dopa ) .25 By inhibiting the enzyme tyrosine hydroxylase with a-methyl-tyrosine, Spector and associ-ates25 demonstrated blockade of endogenous norepinephrine synthesis in guinea pigs. It has not been possible, however, to demonstrate any significant reduction in the synthesis of catecholamines by inhibiting the decarboxylation of dopa to dopamine by treatment with a-methyldopa.4 '7 Other potent decar-Circulation, Volume XXXIV, August 1966 boxylase inhibitors do not appear to have hypotensive properties in man.5' 17 It has been shown '8, 22, 26 that following a single dose of a-methyldopa, decarboxylase inhibition is short-lived, lasting only a few hours. The maximal hypotensive effect of a single intravenous dose of a-methyldopa in man is seen after an interval of 3 to 6 hours, at which time there would be little if any inhibition of decarboxylase. The present study supports the theory that the inhibition of decarboxylase is unrelated to the hypotensive action of a-methyldopa since there was no correlation between the reduction in urinary tyramine and tryptamine and the reduction in blood pressure, and tolerance to the decarboxylase inhibiting action of a-methyldopa with tyrosine as the substrate was demonstrated in four patients, three of whom maintained an excellent hypotensive response to the drug.
The marked increase in the inhibition of decarboxylase following chronic treatment with a-methyldopa was surprising. Cumulation of a-methyldopa and its known metabolites does not occur in the absence of renal failure.3' 5 16, 17 It is possible that amethyldopa or its metabolites can cause less reversible inhibition of decarboxylase under certain conditions. The increase in inhibition was more marked with tryptophan as the substrate than with tyrosine, and in four patients the urinary tyramine levels at the final admission had returned to approximately control levels despite continued reduction in the output of tryptamine. In contrast to these four patients, most of the others showed further lowering of the urinary excretion of both tyramine and tryptamine. These findings suggest the development of an alternate pathway for the formation of tyramine from tyrosine in certain patients. The lack of correlation between the reduction in tyramine excretion and the reduction in tryptamine excretion suggests that the specific activities of decarboxylase as measured by in vitro preparations from guinea pig kidney27 are not readily transferred to in vivo studies in man.
An unexpected finding was the significant increase in the percentage of 3-methoxy-a-methyldopa following the chronic administration of a-methyldopa. Increased activity of some drug metabolizing enzymes of the liver microsomes following the chronic administration of certain drugs is well established. No report is known, however, describing the induction of catechol-O-methyl transferase, the enzyme which forms 3-methoxy-a-methyldopa, and which also largely inactivates free (extracellular) epinephrine and norepinephrine. 28 29 In this study a significant correlation appears to exist between the urinary levels of 3-methoxy-a-methyldopa at the final study and the percentage reduction in the mean overall, standing diastolic, standing systolic, and mean standing blood pressures. It is interesting that no such correlation was observed with the blood pressures measured in the lying position. As the maintenance of blood pressure in the standing position depends on the functional integrity of the sympathetic nervous system, the fact that this correlation apparently exists only for standing blood pressures suggests interference with sympathetic function. Such effects could be brought about by more rapid and complete inactivation of free catecholamines as a result of increased catechol-0-methyl transferase iactivity. Tyce and Stott and their associates30' 31 reported increased levels of 3-methoxy-catecholamines in the urine of some hypertensive patients treated with a-methyldopa, but no studies are known of the effects of a-methyldopa or its metabolites on the action of catechol-O-methyl transferase.
The mechanism of the hypotensive action of a-methyldopa is still unclear. Inhibition of decarboxylase is almost certainly unrelated to hypotensive effects. Sjoerdsma and co-workers'7 felt that a-methyldopamine or possibly a-methyl norepinephrine was the active metabolite and displaced norepinephrine from the tissue storage sites. However, when the much more potent decarboxylase inhibitor methyldopa hydrazine was given together with a-methyldopa, the hypotensive effect of the latter drug was unaffected despite the reduction of urinary methyldopamine to very low levels. Buhs and associates16 were unable to demonstrate any hypotensive effect with a-methyldopamine given orally and intramuscularly to three hypertensive patients. These three patients subsequently responded to oral a-methyldopa with a lowering of blood pressure. In the present study, no correlation was observed between the hypotensive action of a-methyldopa and the percentage of free or conjugated base fractions excreted in the urine. For these reasons, it is difficult to accept that the hypotensive action of a-methyldopa is mediated through methyldopamine. ,8-Hydroxylation of a-methyldopamine yields a-methyl norepinephrine. This amine has been identified as a metabolite of a-methyldopa in mice and rabbits'8 but not in rats.32 33* Carlsson and Lindqvist, 18 Day and Rand, 19 and Pettinger and associates20 have proposed that a-methyl norepinephrine replaces norepinephrine in tissue storage sites and acts as a "false neuro-transmitter" when released at nerve endings following sympathetic nerve stimulation. Day and Rand'9 found that a-methyldopa, amethyldopamine and a-methyl norepinephrine were effective in restoring the responses to tyramine and sympathetic nerve stimulation in a number of animal preparations previously treated with reserpine. They concluded that the storage sites which had been depleted of norepinephrine by treatment with reserpine took up the a-methyl norepinephrine, and that this was subsequently released by tyramine or nerve stimulation. As a-methyl norepinephrine is a weaker pressor agent than norepinephrine, this could explain the hypotension with only mild postural effects and also the lack of clinical or experimental evidence of sympathetic blockade. If a-methyl norepinephrine (like amethyldopamine) is not a substrate for monoamine oxidase, rapid intracellular inactivation cannot take place, so that prolonged tissue depletion of norepinephrine results. Despite *An abstract (no. 52) by Torchiana and associates published in The Pharmacologist (Fall, 1965), p. 145, describes the identification of this metabolite in rats as well.
Circulation, Volume XXXIV, August 1966 the attractiveness of this theory a-methyl norepinephrine has not yet been isolated and identified as a metabolite of a-methyldopa in man,5' 17 although a probable metabolite of a-methyl norepinephrine, 3-methoxy-a-methyl norepinephrine, has been tentatively identified. 3' Norepinephrine depletion is unlikely to be the sole mechanism of the hypotensive action of methyldopa. a-Methyl-m-tyrosine, which is even more active than a-methyldopa in depleting tissue stores of norepinephrine22 has no hypotensive action in the renal hypertensive rat, a preparation in which a-methyldopa has a demonstrable hypotensive effect.34* Although the time of onset of hypotension following treatment with a-methyldopa corresponds reasonably well with the reduction in tissue levels of norepinephrine, this depletion appears to persist long after the return of the blood pressure to normal. Thus the blood pressure returns to previous levels well within 24 hours of a single intravenous dose of a-methyldopa in man, and within 24 to 36 hours after cessation of oral therapy. Hess and co-workers22 demonstrated depletion of heart and brain norepinephrine for more than 113 hours after a single dose of a-methyldopa. Only the L-isomer of a-methyldopa has decarboxylase-inhibiting, norepinephrine-depleting, and hypotensive properties,5' and if the decarboxylation of a-methyldopa is prevented, no depletion of norepinephrine occurs. 24 The application of such results from animal studies to man is hampered by the considerable species differences in the metabolism of a-methyldopa. For example, about 50% of an administered dose of a-methyldopa is decarboxylated in the rat,32 whereas only 5 to 10% is decarboxylated in man. Also, with the exception of the renal hypertensive rat, it is difficult to demonstrate any hypotensive action of a-methyldopa in animals. *Since preparation of this manuscript, Sjoerdsma and associates (Lancet 2: 1092-1094, 1965) have reported on the effects of a-methyltyrosine in man. Decreases in blood pressure were equivocal or absent in patients with essential hypertension. Circulation, Volume XXXIV, August 1966 Any explanation of the mechanism of action of a-methyldopa should also take the side effects into account. The sedation which is so often seen clinically when treatment is started is perhaps related to depletion of brain 5-hydroxytryptamine and dopamine rather than of brain norepinephrine,36 a theory compatible with the fact that sedation clears rapidly when administration of the drug is stopped. The rapid development of tolerance to the sedative effects of a-methyldopa remains unexplained. The mental depression and rare extrapyramidal manifestations37' 38 are very similar to those seen with reserpine and are perhaps more likely to be related to depletion of brain norepinephrine.
Summary
The urinary metabolites of orally administered 2-14C-labeled a-methyldopa were measured in 20 hypertensive patients before and after treatment with a-methyldopa in a dose of 3.0 g daily for 3 months. There was considerable variation in the absorption, biotransformation and excretion of a-methyldopa after an oral dose, but differences in clinical response to a-methyldopa could not be attributed to this.
Approximately 40% of the urinary excretion products of a-methyldopa was recovered as unchanged methyldopa, 31% as a-methyldopa-0-sulfate, 8% as 3-methoxy-a-metlyldopa, 9% as neutral fraction, 3% as free base, and 3%6 as conjugated base.
The percentage of 3-methoxy-a-methyldopa was increased following prolonged treatment with a-methyldopa, suggesting induction of catechol-O-methyl ti[ansferase. The percentage of 3-methoxy-a-methyldopa at the final study was correlated with reductions in standing blood pressure, but not with supine blood pressure. No other changes in the metabolism of a-methyldopa could be attributed to chronic administration of the drug, and no correlation was found between the excretion patterns of the other urinary metabolites of a-methyldopa and hypotensive effect. Tolerance to the hypotensive effect of a-methyldopa occurred in four patients, but in another four an increasing hypotensive effect was seen. The development of tolerance to the hypotensive action of a-methyldopa could not be explained on a metabolic basis.
The inhibition of decarboxylation of tyrosine to tyramine and of tryptophan to tryptamine was studied at the initiation of therapy and again after chronic treatment with amethyldopa. In the majority of patients, inhibition of decarboxylase was markedly increased after chronic treatment, especially when tryptophan was the substrate. In four patients, tolerance to the inhibition of decarboxylation of tyrosine, but not of tryptophan, occurred, and in three of these patients a good hypotensive effect was maintained. There was no correlation between the inhibition of decarboxylase and reduction of blood pressure.
